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Abstract
Background. Uric acid (UA) is known to play a pathogenic
role in chronic kidney disease (CKD). However, its effect
in end-stage renal disease (ESRD) has not yet been eluci-
dated. We explored the prevalence of hyperuricaemia and
the relationship between UA and residual renal function
(RRF) in peritoneal dialysis (PD) patients.
Methods. The subjects of this study were 134 PD patients
who started dialysis at the Yonsei University Health Sys-
tem between January 2000 and December 2005. Timed
urine collections were performed within 1 month of PD
commencement and at 6-month intervals thereafter. The
slope of decline of RRF over time was calculated by lin-
ear regression analysis of serial urinary urea and creatinine
clearances for each patient. Biochemical and clinical data
at the time of initial urine collection were considered as
baseline.
Results. At baseline, 32.8% of the PD patients had hy-
peruricaemia (UA ≥7.0 mg/dl). A significant majority of
patients with hyperuricaemia were diabetic (P= 0.02). Hy-
pertensive patients had a higher UA level (P= 0.002) com-
pared to normotensive patients. The overall reduction rate
of RRF in hyperuricaemic patients was significantly higher
than in the normouricaemic group (P = 0.001). In the mul-
tiple linear regression analysis, hyperuricaemia and history
of DM showed a significant negative correlation with the
reduction rate of RRF after adjusting for demographic data,
comorbid conditions, body mass index, baseline RRF and
medications (P = 0.001).
Conclusions. Hyperuricaemia is common among PD pa-
tients and is significantly associated with the rate of decline
of RRF.
Keywords: end stage renal disease; hypertension; peritoneal dialysis;
residual renal function; uric acid
Introduction
There is an increasing body of evidence indicating that hy-
peruricaemia may have a role in the development of hyper-
tension, kidney disease, cardiovascular events and mortality
[1,2]. This has been well established in animal models that
showed that uric acid (UA) was directly involved in the
development and progression of hypertension and kidney
disease, independent of intrarenal crystal formation [3,4].
The main mechanisms proposed by which UA causes these
conditions involve the activation of the renin–angiotensin–
aldosterone system [5], vascular smooth muscle cell prolif-
eration [6] and impaired endothelial nitric oxide production
[7].
Epidemiologic studies have showed that UA is an inde-
pendent risk factor for the development and progression of
C© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved.
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hypertension [8]. An elevated UA level was also associ-
ated with the progression of kidney disease in the normal
population and in patients with hypertension, diabetes and
chronic kidney disease (CKD) [9–12].
Since the kidney excretes approximately two-thirds of
the UA produced daily, serum UA tends to rise in patients
approaching ESRD. However, it is uncertain whether UA
is a mediator of RRF decline in patients undergoing renal
replacement therapies.
The aims of the present study were to explore the preva-
lence of hyperuricaemia in continuous ambulatory peri-
toneal dialysis patients (CAPD) and to investigate the rela-
tionship between hyperuricaemia and RRF loss.
Subjects and methods
Study population
Clinical and laboratory data were retrieved from the Yonsei PD Unit
Database. The subjects of the study were 151 ESRD patients who started
CAPD between January 2000 and December 2005 with serial urea kinetic
studies, including measurements of RRF. Eight patients who were consid-
ered anuric, with a residual urine volume of <200 ml/day at the time of
the initial urea kinetic study, were excluded. An additional nine patients
who had received prior kidney transplants were excluded due to long-term
use of immunosuppressive agents. Therefore, a total of 134 patients were
included in this study. All patients were initially evaluated for RRF within
1 month of CAPD initiation. Patients were followed up for 24 months or
until their measured urine volume was <200 ml/day.
RRF was calculated as an average of urea and creatinine clearance
from a 24-h urine collection within 1 month of CAPD commencement,
and thereafter at 6-month intervals [13]. Demographic and clinical data in-
cluding sex, age, body mass index, primary renal disease, type of dialysate
used (conventional or biocompatible solution), use of anti-hypertensive
agents (angiotensin-converting enzyme inhibitors or angiotensin II re-
ceptor blockers, calcium channel blockers, beta blockers and diuretics)
and allopurinol were collected as possible predictors of RRF decline.
Different types of PD fluid (Baxter Healthcare, Deerfield, IL, USA; Fre-
senius Medical Care, Deutschland GmbH, Germany; and Gambro, Lund,
Sweden) were used as conventional and biocompatible solutions. Peritoni-
tis rate was recorded during the follow-up period. The following laboratory
data obtained at the time of the initial urea kinetic study were considered
as baseline: haematocrit, albumin, BUN, creatinine, CRP, UA, Kt/V urea,
4-h D/P creatinine and normalized protein catabolic rate (nPCR). Hyper-
tension was defined as a positive history of hypertension or use of antihy-
pertensive agents at the time of PD commencement. Hyperuricaemia was
defined as a serum UA level ≥7.0 mg/dl.
Statistical analysis
Statistical analysis was performed using SPSS for Windows software,
version 12.0 (SPSS Inc., Chicago, IL, USA). All data were expressed as
mean ± SD. Due to the log-normally distributed value of RRF, the natural
log values were used for analysis, and geometric means were calculated
and reported with 95% confidence intervals (CI). We intended to predict
the rate of change of RRF during the follow-up with variables, including
the UA levels measured at baseline. The reduction rate of RRF over time
was determined using least squares linear regression of RRF on time; this
was calculated from serial urinary urea and creatinine clearances mea-
sured during the study period for each patient. The slope was expressed as
the regression coefficient (ml/min/month/1.73 m2). Two data points were
used for calculating the regression coefficient in patients who had less
than three measurements. It has been proposed that RRF declines expo-
nentially, and therefore, the regression coefficient was calculated on both
linear and logarithmic scales of RRF in order to assess the nature of RRF
reduction [14]. Since the logarithmic scale of RRF showed a better linear
correlation with the follow-up time, the reduction rate of RRF was cal-
culated as the follow-up duration against RRF on a logarithmic scale. To
compare differences between the hyperuricaemia and normal UA groups,
Student’s t-test and the χ2 test were used. Pearson’s correlation analysis
was performed to estimate the correlation between the rate of reduction
Table 1. Demographic and baseline clinical data (n = 134)
Age (years) 53.8 ± 13.2
Gender (male/female) 59/75
History of diabetes mellitus 46 (34.3%)
Hypertension 112 (83.6%)
Body mass index (kg/m2) 22.6 ± 2.8
Weekly Kt/V urea 2.6 ± 0.8
4-h D/P creatinine 1.1 ± 0.4
RRF (ml/min/1.73 m2) 4.8 (4.4–5.6)
Primary kidney disease
Diabetes 44 (32.8%)
Hypertension 34 (25.4%)
Glomerulonephritis 20 (14.9%)
Others 36 (26.9%)
BUN (mg/dl) 46.8 ± 16.3
Creatinine (mg/dl) 6.6 ± 2.2
Haematocrit (%) 33.7 ± 6.5
Albumin (mg/dl) 3.6 ± 0.6
CRP (mg/dl) 0.35 ± 0.55
Total cholesterol (mg/dl) 191.7 ± 40.0
UA (mg/dl) 6.6 ± 1.5
nPCR (g/kg/day) 1.1 ± 0.4
Medication
ACE inhibitors or ARBs 78 (58.2%)
Calcium channel blockers 97 (72.3%)
Diuretics 70 (52.2%)
Beta blockers 68 (50.7%)
Allopurinol 15 (11.2%)
Dialysate
Conventional 33 (24.6%)
Biocompatible solutions 101 (75.4%)
Peritonitis rate (times/patient-years) 0.2 ± 0.5
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor
blocker; nPCR, normalized protein catabolic rate.
Data are expressed as mean ± SD or geometric mean (95% CI).
of RRF and other variables. Multiple linear regression analysis was used
to identify significant determinants of the RRF reduction rate. In order to
confirm the difference of RRF change over time between hyperuricaemia
and normouricaemia groups, repeated measures ANCOVA analysis was
used. When comparing time periods, the paired sample t-test was used
for continuous variables and McNemar’s test was used for categorical
variables. For multiple regressions and repeated measures ANCOVA, ad-
justments were made for demographic factors, comorbid conditions, body
mass index, baseline RRF and medications. A P-value of <0.05 was con-
sidered statistically significant.
Results
Demographic characteristics and biochemical data
The clinical characteristics of the patients are shown in
Table 1. The mean age was 53.8 ± 13.2 years, and 59
(44%) of the subjects were male. Diabetes was the most
common cause of ESRD in this study (32.8%). The mean
UA level was 6.6 ± 1.5 mg/dl with a range of 3.0–12.3
mg/dl. All patients were prescribed CAPD with a daily
dialysate volume of 8 l.
Comparison between patients with hyperuricaemia and
those with normal UA levels
At baseline, 32.8% of the patients had UA levels >7 mg/dl.
When patients were divided into two groups on the basis
of UA concentrations, there were no significant differences
in age (54.9 ± 12.9 versus 51.1 ± 13.7 years, P = 0.13),
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Table 2. Comparison of clinical and biochemical characteristics between
hyperuricaemic patients and patients with normal UA levels
UA <7 mg/dl UA ≥7 mg/dl
(n = 90) (n = 44)
Age (years) 54.9 ± 12.9 51.3 ± 13.7
Gender (male/female) 35/55 24/20
Diabetes 25 (27.8%) 21 (47.7%)∗
Hypertension 69 (76.7%) 43 (97.7%)∗∗
Body mass index (kg/m2) 22.5 ± 2.8 22.8 ± 3.0
Weekly Kt/V urea 2.7 ± 0.8 2.5 ± 0.7
4-h D/P creatinine 0.77 ± 0.13 0.72 ± 0.14
RRF (ml/min/1.73 m2) 5.0 (4.2–5.9) 5.0 (3.9–6.0)
Albumin (mg/dl) 3.5 ± 0.5 3.7 ± 0.8
CRP (mg/dl) 0.35 ± 0.59 0.36 ± 0.49
Total cholesterol (mg/dl) 195.3 ± 39.5 184.6 ± 40.3
nPCR (g/kg/day) 1.1 ± 0.3 1.1 ± 0.4
Allopurinol use 12 (17.1%) 3 (8.6%)
Peritonitis rate (times/
patient-years)
0.2 ± 0.6 0.1 ± 0.4
RRF, residual renal function; nPCR, normalized protein catabolic rate.
Data are expressed as mean ± SD or geometric mean (95% CI).
∗P < 0.05, ∗∗P < 0.01 versus UA <7 mg/dl group.
body mass index (22.5 ± 2.8 versus 22.8 ± 3.0 kg/m2,
P = 0.56), proportion of males (38.9 versus 54.5%, P =
0.09), serum albumin (3.5 ± 0.5 versus 3.7 ± 0.8 mg/dl,
P= 0.07), serum cholesterol (195.3 ± 39.5 versus 184.6 ±
40.3 mg/dl, P = 0.15) and serum CRP (0.35 ± 0.59 versus
0.36 ± 0.49 mg/dl, P = 0.95) between the two groups. In
addition, nPCR (1.1 ± 0.3 versus 1.1 ± 0.4 g/kg/day, P =
0.51), baseline RRF (5.0; 95% CI: 4.2–5.9 versus 5.0; 95%
CI: 3.9–6.0 ml/min/1.73 m2, P= 0.85), D/P creatinine ratio
(0.77 ± 0.13 versus 0.72 ± 0.14, P = 0.05), weekly Kt/V
urea (2.7 ± 0.8 versus 2.5 ± 0.7, P = 0.18), the number of
patients on allopurinol (17.1 versus 8.6%, P = 0.38) and
peritonitis rate (0.2 ± 0.6 versus 0.1 ± 0.4 times/patient-
years, P = 0.65) did not differ between the two groups.
However, the proportion of patients with the history of
diabetes was significantly higher in hyperuricaemic patients
(27.8 versus 47.7%, P = 0.02) (Table 2). There was no
correlation between baseline RRF and UA level (r=−0.13,
P = 0.21).
Consistency of serum UA levels
The prevalence of hyperuricaemia did not change at the
12-month follow-up (32.8 versus 33.3%, P = 1.0), and the
mean UA values also remained unchanged (6.64 ± 1.45
versus 6.63 ± 1.50 mg/dl, P = 0.97). There was a positive
and statistically significant correlation between baseline
serum UA levels and mean serum UA levels (r = 0.80, P<
0.001).
UA and hypertension
Hypertension was observed in 83.6% of the patients start-
ing PD. The proportion of patients with hypertension was
significantly higher in hyperuricaemic patients (76.7 versus
97.7%, P < 0.001) (Table 2). In addition, the UA level was
higher in PD patients with hypertension compared to those
Fig. 1. Patients who did not have hypertension showed significantly lower
mean UA levels compared to hypertensive patients. Each bar shows the
mean and standard deviation of the mean. ∗P < 0.05 versus patients
without hypertension.
without hypertension (6.8 ± 1.6 versus 5.7 ± 0.9 mg/dl,
P = 0.002) (Figure 1).
UA and reduction rate of RRF
All patients had a minimum of two timed urine collec-
tions to measure RRF (90.3% had at least three collections
performed). A significant correlation was found between
the follow-up duration and the exponential decline of RRF,
with a correlation coefficient (r) of 0.469 (P < 0.001).
In contrast, when RRF was represented on a linear scale,
the decline of RRF and the follow-up duration showed a
weaker linear correlation (r = 0.328, P < 0.001). There-
fore, the follow-up duration and RRF were better correlated
logarithmically.
During the study period, the overall RRF declined
more rapidly in hyperuricaemic patients than in the nor-
mouricaemic group (−0.20 ± 0.17 versus −0.08 ±
0.20 ml/min/month/1.73 m2, P = 0.001).
Hyperuricaemia had an inverse relation with the reduc-
tion rate of RRF (β = −0.35, P = 0.001). A negative
relationship with the reduction rate of RRF was also found
in males (β = −0.21, P = 0.02) and diabetics (β = −0.36,
P < 0.001). However, there was no significant correlation
between the reduction rate of RRF and body mass index
(β = −0.16, P = 0.07), diuretic use (β = −0.04, P =
0.67), use of angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers (β = −0.03, P = 0.76) or
peritonitis rate (β = −0.15, P = 0.08). The use of bio-
compatible solutions also showed no association with the
rate of RRF decline (β = 0.01, P = 0.91). Multivariate lin-
ear regression analysis showed that the history of diabetes
(β = −0.26, P= 0.02) and hyperuricaemia at baseline (β =
−0.36, P = 0.001) were associated with the reduction rate
of RRF independent of age, gender, history of diabetes and
hypertension, body mass index, baseline RRF and medi-
cations (Table 3). When further analysis was done using
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Table 3. Multiple linear regression analysis between the reduction rate of
RRF and other variables
Univariate Multivariate
Variables β P-value β P-value
Hyperuricaemia (uric acid
≥7 mg/dl)
−0.35 0.001 −0.36 0.001
Age (years) 0.08 0.38 0.10 0.24
Male −0.21 0.02 −0.06 0.46
History of DM −0.36 <0.001 −0.25 0.001
History of hypertension −0.05 0.58 0.03 0.76
Body mass index (kg/m2) −0.16 0.07 −0.11 0.20
Baseline RRF
(ml/min/1.73 m2)
−0.27 0.003 −0.21 0.01
nPCR (g/kg/day) −0.03 0.70 0.05 0.53
Use of biocompatible
solutions
0.01 0.91 0.04 0.60
Peritonitis rate
(times/patient-years)
−0.15 0.08 −0.04 0.59
Diuretic use −0.04 0.67 0.02 0.78
Allopurinol use −0.01 0.87 −0.01 0.93
RRF, residual renal function; ACE, angiotensin-converting enzyme; ARB,
angiotensin II receptor blocker.
Fig. 2. Changes in log RRF over time between hyperuricaemic (uric acid
≥7 mg/dl) and patients with normal uric acid levels (uric acid <7 mg/dl).
Means and error bars are presented for each visit. RRF, residual renal
function.
repeated measures ANCOVA, a significant interaction ef-
fect was found between time and UA groups (F(4.0, 160.0) =
2.77, P = 0.03). Additionally, the between-subjects effect
comparing the hyperuricaemic and normouricaemic groups
was significant (F(1, 40) = 5.88, P = 0.02) with adjustment
for age, sex, DM, hypertension, BMI, baseline RRF and
medications, which suggests that changes in log RRF were
independently influenced by UA levels. The plot in Figure 2
shows almost equal levels of RRF at baseline, but at follow-
up higher RRF levels were found in patients with lower UA
at baseline.
Discussion
In the present study, we found that hyperuricaemia is com-
mon among ESRD patients on CAPD, occurring in ∼30%
of the population. Additionally, hypertensive patients had
higher UA levels, suggesting a close relationship between
UA and hypertension. An important finding of our study is
that baseline UA level was independently associated with
the rate of RRF decline, even after adjustment for renal
function at baseline.
Due to the progressive loss of glomerular filtration,
ESRD patients have lower renal UA clearance and higher
serum UA levels. In a study by Ifudu et al. [15], the mean
serum UA level in maintenance haemodialysis patients was
7.6 ± 1.8 mg/dl (7.6 ± 1.8 mg/dl in men and 7.5 ±
1.6 mg/dl in women). In our study, the mean UA level was
lower, and although there was no statistical significance,
men tended to have a higher UA level than women (6.8 ±
1.4 versus 6.5 ± 1.6 mg/dl, P = 0.15). The lower UA levels
in our study may have been due to the fact that only ESRD
patients with significant RRF were recruited. However, UA
levels in our population were still higher than in the general
population [16].
Serum UA has been assumed to be involved in the de-
velopment of hypertension [8]. Even though hypertension
is a common feature in ESRD patients, the role of UA in
the development and progression of hypertension in this
population is not well understood. We have shown that hy-
pertensive patients on PD have higher UA levels. Although
a causal relationship between hypertension and UA was
not shown, our preliminary data reveal that there may be
an association between hypertension and UA in the ESRD
population.
UA has been proposed to be associated with renal dis-
ease. UA-induced preglomerular arterial disease, renal in-
flammation and activation of RAS and COX-2 have been
demonstrated as potential mechanisms by which UA acts
on the progression of renal disease [5,17,18]. Several clin-
ical studies have confirmed that UA is an independent risk
factor for the development of renal disease in the normal
population as well as in patients with previous kidney dis-
ease, such as IgA nephropathy [9,11]. Additionally, in the
renal transplant recipient population, a relationship between
UA and graft dysfunction has been demonstrated [19]. In a
recent community-based prospective study of 13 338 par-
ticipants, UA level was described to be an independent risk
factor for the development of kidney disease and mortality
[20]. However, to date very little information is available in
the literature on the role of UA in patients on dialysis.
The present data show that during the initial 2 years of
PD commencement, UA level was independently associ-
ated with the rate of RRF decline, even after adjusting for
baseline RRF. This suggests that UA may be a risk factor
for RRF decline among ESRD patients on PD.
Several studies have found that RRF is an essential
marker of patient and technique survival during PD [21–
25]. A cohort study of 1446 PD patients showed that each
10 l/week/1.73 m2 increase in the urinary component of
weekly creatinine clearance was associated with a 40%
decreased risk of death [26]. The ADEMEX study and
re-analysis of the CANUSA study have clearly demon-
strated that the predictive power for mortality in patients on
PD was attributed to RRF [21,27]. However, strategies for
preserving RRF are limited. Based on the present results,
lowering UA in PD patients could benefit RRF preserva-
tion. However, the use of allopurinol had no effect on RRF
preservation in this study. The fact that there was no differ-
ence in the proportion of patients prescribed for allopurinol
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between the hyperuricaemic and normal UA groups implies
that the medication had not been properly used to lower UA
levels. In order to prove the causal relationship between UA
and RRF, further prospective studies should be performed
that examine the effect of lowering UA on RRF.
In verifying the correlation between UA with the rate
of RRF decline, a logarithmic value of RRF was used.
RRF showed a better linear correlation with the follow-up
duration when represented on a logarithmic scale, which
was in concordance with previous reports [14,28].
Not surprisingly, we found that the history of diabetes
was negatively associated with the rate of RRF decline. Di-
abetes, as well as hypertension, has been recognized as a risk
for renal function loss in chronic renal failure patients. The
presence of diabetes in predicting RRF loss, particularly
in the PD population, has also been mentioned in previous
epidemiologic studies [29,30]. There have been confound-
ing reports on the effect of biocompatible solutions on the
preservation of RRF [31,32]. In our study, there were no dif-
ferences in baseline characteristics between patients using
conventional and biocompatible solutions (data not shown).
Nevertheless, we found no association between the use of
biocompatible solutions and the RRF reduction rate.
There are a number of limitations to this study. This is an
observational and relatively small study without interven-
tion. Therefore, it is quite difficult to determine the current
observation as a cause or consequence. Further randomized
controlled trials intentionally lowering UA levels should be
needed to clarify this issue. In addition, single measures
of UA levels could have reflected acute changes in UA
that might have been induced by diet or exercise. However,
the mean UA level and proportion of hyperuricaemic pa-
tients did not change during a 1-year period, indicating that
serum UA levels were consistent during the study period af-
ter PD commencement. Despite these limitations, it should
be noted that UA was independently associated with the
rate of RRF decline.
In conclusion, this study shows that hyperuricaemia is
a common finding in CAPD patients, and the rate of RRF
loss was significantly related to baseline UA level in CAPD
patients. These results suggest that there is an association
between UA level and the decline rate of RRF in patients
on PD.
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Abstract
Methods. We aimed to clarify arteriosclerotic risk and
to document possible relationships between cardiovascular
risk factors and echocardiographic parameters in paediatric
peritoneal dialysis (PD) patients. M-mode/Doppler/tissue
Doppler echocardiographic studies and lipid/lipoproteins,
homocysteine, high-sensitivity C-reactive protein (HS-
CRP) levels and carotid intima–media thickness (CIMT)
were determined in 59 patients (age: 14.2 ± 4.5 years) and
in 36 healthy subjects.
Results. Structural and functional cardiac abnormalities
were observed in patients on maintenance dialysis. In-
creased left ventricular mass index (LVMI, P = 0.000), rel-
ative wall thickness (P = 0.000), myocardial performance
index (MPI, P = 0.000) were documented in the patients.
Lipoprotein (a) (P = 0.000), homocysteine (P = 0.001),
HS-CRP (P = 0.000) and CIMT (P = 0.000) were signifi-
cantly elevated in the patients. Left ventricular hypertrophy
(LVH) was prevalent in 68% of the patients. Patients with
LVH had higher levels of HS-CRP (P = 0.001) and CIMT
(P = 0.028) than those without LVH. Haemoglobin was an
independent predictor of LVMI (β: −8.9, P= 0.001), while
residual diuresis and CIMT were independent predictors of
diastolic dysfunction (β: −0.45, P = 0.034 and β: 5.90,
P = 0.008, respectively). Albumin (β: −0.72, P = 0.018)
and Kt/V urea (β: −0.48, P = 0.012) were significant pre-
dictors of CIMT. There were positive correlations between
LVMI and CIMT. HS-CRP was positively correlated with
LVMI as well as CIMT.
Conclusions. Elevated levels of atherosclerotic/
inflammatory risk factors, low haemoglobin levels
and loss of residual renal function and their negative
effects on heart are of remarkable importance in paediatric
patients on maintenance peritoneal dialysis. Achieving
recommended targets for haemoglobin, blood pressure and
Kt/V urea, preserving residual renal function as well as
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